
Ruijin Hospital Shen Baiyong Team Pancreatic Cancer Triplet Therapy Study Presented at ESMO Annual Meeting
Shen Baiyong's team released preliminary results of the world's first phase II study using a chemotherapy+targeted+immunotherapy triplet for perioperative KRAS G12D-mutant pancreatic cancer. ORR improved from 30% to 87% with 100% resection rate, offering a new treatment paradigm for pancreatic cancer.
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
